Guizhou Yibai Pharmaceutical Co., Ltd. (SHA:600594)

SHA:600594 Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-349.7	-329.56	-317.22	103.4	-426.39	243.77
Depreciation & Amortization	171.3	171.3	192.69	201.11	181.48	149.94
Other Amortization	21.89	21.89	34.34	28.16	46.9	53.24
Loss (Gain) From Sale of Assets	27.21	27.21	-0.78	-0.02	-31.05	1.37
Asset Writedown & Restructuring Costs	135.28	135.28	58.02	19.93	627.43	142.19
Loss (Gain) From Sale of Investments	0.21	0.21	-0.34	-0.03	-1.83	-34.64
Provision & Write-off of Bad Debts	3.19	3.19	-5.04	-3.19	-0.27	7.43
Other Operating Activities	113.29	55.5	42.02	104.2	49.38	72.84
Change in Accounts Receivable	145.72	145.72	184.28	44.61	69.38	241.25
Change in Inventory	76.68	76.68	41.75	-26.6	-88.41	-87.09
Change in Accounts Payable	-60.46	-60.46	-105.38	-88.77	-57.63	137.14
Operating Cash Flow	294.36	256.71	86.87	377.61	345.3	934.21
Operating Cash Flow Growth	-	195.50%	-76.99%	9.36%	-63.04%	154.79%

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-35.92	-34.99	-96.32	-130.38	-322.92	-447.78
Sale of Property, Plant & Equipment	7.59	6.9	1.17	0.09	4.78	6.63
Cash Acquisitions	-	-	-	-	-	-332.04
Divestitures	-	-	-	-	-	-18.56
Investment in Securities	-	-	-19.99	-	-20	100.71
Other Investing Activities	0.2	0.08	11.3	14.7	30.37	3.37
Investing Cash Flow	-28.13	-28	-103.84	-115.59	-307.78	-687.67

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Long-Term Debt Issued	-	516	560	741.33	895.7	1,095
Long-Term Debt Repaid	-	-766.88	-607.83	-850.84	-743.72	-1,393
Net Debt Issued (Repaid)	-184.18	-250.88	-47.83	-109.51	151.98	-297.81
Repurchase of Common Stock	-	-	-25	-	-	-
Common Dividends Paid	-26.21	-28.69	-86.87	-41.18	-49.11	-152.12
Other Financing Activities	-23	-23	-	-1	66	-35.08
Financing Cash Flow	-233.39	-302.57	-159.71	-151.69	168.87	-485.01

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-0.02	-0.01	-0	-	-	-
Net Cash Flow	32.82	-73.87	-176.67	110.33	206.39	-238.47

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	258.44	221.71	-9.45	247.23	22.38	486.43
Free Cash Flow Growth	-	-	-	1004.93%	-95.40%	-
Free Cash Flow Margin	15.02%	11.90%	-0.43%	8.77%	0.82%	14.54%
Free Cash Flow Per Share	0.33	0.28	-0.01	0.31	0.03	0.61
Levered Free Cash Flow	310.39	274.8	89.93	150.26	-107.51	288.92
Unlevered Free Cash Flow	323.59	289.41	106.42	163.78	-84.09	310.88

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Income Tax Paid	154.43	162.35	193.74	318.26	304.93	379.86
Change in Working Capital	171.67	171.67	83.19	-75.95	-100.34	298.07

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 30, 2026

Data Sources Report a data error